Wise announces the closing of €15m Series C financing led by CDP Venture Capital

– ITALY, Milan –  WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round led by CDP Venture Capital SGR, and including Indaco Ventures I Fund and EUREKA! Venture SGR, joining existing investors participating in this round – Principia SGR, New Frontier, Atlante Seed and Atlante Ventures, High Tech Gründerfonds and F3F.

The proceeds will be partially used to accelerate the development of the second product, SCS EXPERT, a percutaneously implantable multi-column paddle lead for Spinal Cord Stimulation. The funds will also support the upcoming launch of its first product, WISE Cortical Strip, a single-use medical device for IntraOperative Neurophysiological Monitoring during brain tumor and epilepsy surgeries, which is anticipating the granting of its CE mark.

This financing adds to the recent European Commission grant of EUR 2.3 million given to WISE in July 2020, to support the development and launch of SCS EXPERT within the EIC Accelerator program of Horizon 2020.

“We are delighted with the support we have received for our latest funding round and welcome our new investors,” said CEO, Luca Ravagnan. “With this additional funding, we will be able to accelerate our plans to launch SCS EXPERT, as we make progress toward FDA clearance and market launch.”

He added, “With support from our engaged investors, we remain committed to build on our innovative drive and passion to provide the best lead with the least invasive implantation procedure to the SCS market, potentially bringing higher relief to patients suffering from chronic pain and other disorders.”

Chronic pain is a debilitating disease for sufferers and treatment costs billions for the European and US healthcare systems each year. Globally, around 328 million people suffer from high-impact chronic pain – pain that lasts three months or longer and is accompanied by at least one major activity restriction.

To date, the therapeutic market has been dominated by drugs from several classes including nonsteroidal anti-inflammatory drugs and opioid analgesics. However, the increased scrutiny of opioid use worldwide has led to a significant rise in interest in alternative treatments, such as neuromodulation using SCS implants. The current neuromodulation market has an estimated value of $5.8 billion, with over 50% of the value given by the SCS sector.

SCS implants work by blocking pain signals before they reach the brain through the delivery of electrical stimuli to the spinal cord by means of implantable leads. Currently, there are two types of implantable leads available – multi-column paddle leads and cylindrical leads. Multi-column paddle leads offer better overall treatment results, but current products can only be inserted surgically.

Thanks to its proprietary SCBI technology, WISE is the first company capable of producing a multicolumn paddle lead – the SCS EXPERT – that can be folded in a catheter and implanted percutaneously like a cylindrical lead, i.e. with no surgical intervention required. This will offer the opportunity to the patient for the first time to receive the best SCS lead with the least invasive implantation procedure.

New investor, Laura Scaramella, Partner at CDP Venture Capital SGR said: “We are delighted to support WISE’s brilliant team in this important phase. The technological advantage deriving from the unique characteristics of the proprietary technologies underlying its medical leads has been validated with the first product, WISE Cortical Strip. We are confident this will be a distinctive feature also of SCS EXPERT, thus confirming the enormous potential that WISE has in its ability to offer cutting-edge solutions to unmet medical needs, hence to improve quality of life of millions of people.”

New investor, Massimo Gentili from EUREKA! Venture SGR added: “WISE’s sound and consistent IP package and the material-based approach originally developed at the University of Milan nicely fits with EUREKA!’s goals. The experienced management team and a clear path to the market confirms the high potential of their technology. The excellence in developing the technological platform from research to a product that is ready-to-be-launched demonstrates that Italian technology transfer deals are feasible.”

Paolo Siviero from Principia SGR added: “WISE has made significant progress since we first invested in 2015 and we are pleased to continue supporting the Company’s work. We believe the SCS Expert leads will be a major step forward in the treatment of chronic pain and provide an important alternative treatment for patients. The Company has a clear commercialization strategy for its lead product and the technology to create further innovative products.”

Davide Turco, CEO of Indaco Venture Partners SGR concluded: “Our Funds have been supporting WISE since the Seed stage and we are very pleased that thanks to its outstanding team and technology, the Company has been able to raise this new important equity round by qualified investors. We are delighted to participate in this round again with our latest fund, Indaco Ventures I, with the core mission to finance large equity rounds that enable advanced technologiesto reach the market.”

About WISE

WISE S.r.l. has developed a genuinely new generation of leads for neuromonitoring, neuromodulation and brain-machine interfacing by means of its proprietary Supersonic Cluster Beam Implantation technology.

Neuromonitoring and neuromodulation require electrodes and leads to be surgically implanted on neural tissues to apply electrical stimuli or to record the electrical activity. The leads produced using WISE’s new SCBI technology consist of stretchable electronic circuits integrated in very thin elastomeric foils. As a result, WISE’s electrodes are highly ergonomic, conformable, soft and thin, thus allowing great adhesion, minimal invasiveness and excellent adaptability on neural tissues.

In parallel with the development of the SCS EXPERT lead, WISE will be soon launching the WISE Cortical Strip, a single-use medical device for IntraOperative Neurophysiological Monitoring during brain tumor and epilepsy surgeries. The WCS is used for continuous recording of the brain’s electrical activity and for brain stimulation. The Company has applied for its CE mark.

Founded in 2011 by a team of material scientists coming from the University of Milan, WISE has so far received funding from Agite!, Atlante Seed and Atlante Ventures, b-to-v, HTGF, Principia SGR, New Frontier and private investors, and closed a Series C funding round in 2020 with new investors. In 2016, the Company established its production plant in Cologno Monzese, Milan, Italy and has an office in Berlin, Germany.

For more information: https://www.wiseneuro.com/

About CDP Venture Capital SGR

CDP Venture Capital SGR – Fondo Nazionale Innovazione CDP Venture Capital is an asset management company with an AuM of €1 billion. The mission of the firm is to make Venture Capital a strategic pillar to Italy’s economic growth and innovation, creating the conditions for a comprehensive and sustainable growth of the Venture Capital ecosystem. It operates through a set of funds that aim to support startups in all their development phases and through a mix of direct and indirect investments

For more information: https://www.cdpventurecapital.it/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.